HealthTree

Showing 113 trials matching your filters.

Study of E7777 Prior to Kymriah for R/R DLBCL

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the ...

DRUG: E7777

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced st...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

OTHER: Electronic Health Record Review

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibito...

DRUG: LP-168

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B...

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refract...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Loncastuximab Tesirine

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituxi...

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of ...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/prednisolone

DRUG: Bendamustine

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Folli...

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 (Mevrometostat) in Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

DRUG: Mervometostat (PF-06821497)

DRUG: Enzalutamide

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell N...

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more abou...

DRUG: Odronextamab

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular L...

This randomized phase I/II trial studies radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma. Radiation therapy uses high energy x-rays to kill cancer cells. Immunotherapy with monoclonal antibo...

OTHER: Clinical Observation

RADIATION: Radiation Therapy

BIOLOGICAL: Rituximab

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Agg...

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), f...

BIOLOGICAL: Zilovertamab vedotin

DRUG: Nemtabrutinib

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of D...

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab ...

PROCEDURE: Bone Marrow Biopsy

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Prednisone

BIOLOGICAL: Retifanlimab

BIOLOGICAL: Rituximab and Hyaluronidase Human

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Multigated Acquisition Scan

OTHER: Fludeoxyglucose F-18

PROCEDURE: Positron Emission Tomography

PROCEDURE: Computed Tomography

PROCEDURE: Biospecimen Collection

DRUG: Polatuzumab Vedotin

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-...

This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment...

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

DRUG: Polymer-conjugated IL-15 Receptor Agonist NKTR-255

PROCEDURE: X-Ray Imaging

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Lumbar Puncture

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Biospecimen Collection

PROCEDURE: Biopsy

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Co...

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treat...

DRUG: Tazemetostat

DRUG: Placebo oral tablet

COMBINATION_PRODUCT: Lenalidomide

COMBINATION_PRODUCT: Rituximab

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study...

DRUG: Epcoritamab

DRUG: Rituximab

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refra...

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Lenalidomide

DRUG: Rituximab

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Rela...

To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Valemetostat

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent ...

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

BIOLOGICAL: EO2463

DRUG: lenalidomide

BIOLOGICAL: rituximab

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunother...

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

DRUG: Epcoritamab

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibod...

DRUG: Bendamustine Hydrochloride

DRUG: Brentuximab Vedotin

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine a...

This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematol...

BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells

DRUG: Bendamustine

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-hum...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: ACE1831

DRUG: Obinutuzumab

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

A Study of Mosunetuzumab in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

DRUG: Mosunetuzumab

DRUG: Zanubrutinib

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axic...

DRUG: Acalabrutinib

BIOLOGICAL: Axicabtagene Ciloleucel

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligi...

This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back ...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

DRUG: Carboplatin

PROCEDURE: Computed Tomography

DRUG: Etoposide

DRUG: Ifosfamide

DRUG: Lenalidomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tafasitamab

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

BIOLOGICAL: CNTY-101

BIOLOGICAL: IL-2

DRUG: Lymphodepleting Chemotherapy

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in...

DRUG: ABBV-291

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall sur...

DRUG: CD22CART Infusion

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Othe...

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabr...

DRUG: Acalabrutinib

BIOLOGICAL: Obinutuzumab

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lympho...

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maxim...

DRUG: Selinexor

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

DRUG: NX-2127

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden ...

To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

DRUG: Obinutuzumab

DRUG: CC-99282

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.

BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)

BIOLOGICAL: CD19 targeted CAR T Cell Therapy

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With ...

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alon...

PROCEDURE: Biospecimen Collection

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Oral Azacitidine

DRUG: Prednisone

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in...

DRUG: IKS03

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large ...

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabta...

BIOLOGICAL: Axicabtagene Ciloleucel

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Fludarabine

BIOLOGICAL: Lisocabtagene Maraleucel

BIOLOGICAL: Mosunetuzumab

OTHER: Patient Observation

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Tisagenlecleucel

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.

DRUG: Efineptakin alfa

DRUG: Tisagenlecleucel

DRUG: Axicabtagene ciloleucel

DRUG: Lisocabtagene Maraleucel

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Particip...

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

DRUG: Golcadomide

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Bendamustine

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone ...

BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycl...

DRUG: Mosunetuzumab

DRUG: Lenalidomide

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most co...

DRUG: ABBV-319

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well ...

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participa...

DRUG: Odronextamab

DRUG: Rituximab

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone/Prenisolone

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two tar...

DRUG: Mosunetuzumab

DRUG: Polatuzumab vedotin

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Ly...

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a t...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

BIOLOGICAL: Mosunetuzumab

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to ...

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Lenalidomide

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Positron Emission Tomography

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Tafasitamab

DRUG: Tazemetostat

DRUG: Zanubrutinib

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Maligna...

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

BIOLOGICAL: CTX112

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin L...

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, ma...

DRUG: CD47 Antagonist ALX148

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B...

DRUG: AZD0486 IV

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin ...

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzu...

DRUG: Polatuzumab vedotin

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

DRUG: SGR-1505

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabr...

DRUG: ACALABRUTINIB

DRUG: LISOCABTAGENE MARALEUCEL

DRUG: Lymphodepleting chemotherapy

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

DRUG: Zanubrutinib

DRUG: Rituximab

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Ly...

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed ...

DRUG: Cyclophosphamide

DRUG: Doxorubicin Hydrochloride

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

DRUG: Zanubrutinib

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient S...

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess th...

DRUG: Epcoritamab

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD2...

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.

DRUG: AZD5492

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal res...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Golcadomide

PROCEDURE: Positron Emission Tomography

BIOLOGICAL: Rituximab

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of Hi...

This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendam...

DRUG: Bendamustine

DRUG: Rituximab

DRUG: Tazemetostat

Emapalumab Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: ...

DRUG: Emapalumab

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

DRUG: Axicabtagene Ciloleucel

TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large ...

This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

DRUG: Ontorpacept

BIOLOGICAL: Pembrolizumab

PROCEDURE: Positron Emission Tomography

DRUG: Maplirpacept

PROCEDURE: Biopsy

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs:...

DRUG: CD79b-19 CAR T cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

DRUG: Docirbrutinib

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

DRUG: BGB-16673

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their ly...

DRUG: Obinutuzumab

DRUG: Glofitamab

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in ...

DRUG: Mosunetuzumab

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through th...

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult partici...

DRUG: ABBV-101

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Ref...

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

DRUG: ATA3219

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (M...

DRUG: Tazemetostat Pill

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Ther...

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

DRUG: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine phosphate

DRUG: Prednisone

DRUG: Diphenhydramine

DRUG: Acetaminophen

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicu...

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

DRUG: Loncastuximab tesirine

DRUG: Rituximab

CAR-T Followed by Bispecific Antibodies

The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who ...

DRUG: mosunetuzumab

DRUG: glofitamab

DRUG: obinutuzumab

Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find t...

DRUG: IMT-009

COMBINATION_PRODUCT: Fruquintinib

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lympho...

This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (rel...

DRUG: Venetoclax

DRUG: Lenalidomide

BIOLOGICAL: Rituximab

BIOLOGICAL: Rituximab and Hyaluronidase Human

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the ...

DRUG: AC676

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators h...

DRUG: Mosunetuzumab

DRUG: Tazemetostat Pill

Study of IMPT-314 in R/R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three co...

DRUG: IMPT-314

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancie...

DRUG: L-Bcl-2 antisense oligonucleotide

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grad...

This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refra...

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Magnetic Resonance Imaging

BIOLOGICAL: Mosunetuzumab

DRUG: Polatuzumab Vedotin

PROCEDURE: Positron Emission Tomography

OTHER: Questionnaire Administration

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cem...

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy ...

DRUG: ONM-501

DRUG: Cemiplimab

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory...

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisati...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: JCAR017

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab ...

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymp...

DRUG: Odronextamab

DRUG: Lenalidomide

DRUG: Rituximab

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma...

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not ...

DRUG: Soquelitinib

DRUG: Belinostat

DRUG: Pralatrexate

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic ...

RADIATION: Bridging radiation therapy

BIOLOGICAL: Liso-cel

RADIATION: Post-infusion radiation

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called...

BIOLOGICAL: Loncastuximab Tesirine

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed ac...

DRUG: Ibrutinib

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ H...

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

DRUG: SYNCAR-001

DRUG: STK-009

DRUG: Cyclophosphamide

DRUG: Fludarabine

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Prednisone

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Cyclophosphamide

DRUG: Obinutuzumab

DRUG: Bendamustine

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the grow...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Vincristine

DRUG: Prednisone

DRUG: Etoposide

DRUG: Duvelisib

DRUG: Oral azacitidine

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

BIOLOGICAL: bbT369

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymp...

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: anti-CD19 CAR-T cells

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Ce...

This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's B-cell lymphoma or chronic...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

BIOLOGICAL: Tocilizumab

Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refr...

This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma. The hypothesis of...

DRUG: Mosunetuzumab

DRUG: DHAX

DRUG: ICE

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

DRUG: Fenretinide

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

DRUG: SC262

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

DRUG: NX-5948

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refra...

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells called EGFRt/19-28z/IL-12 CAR T cells, and to see how they work in treating patients with hematologic malignancies that makes a protein called CD19 (CD19...

PROCEDURE: Biopsy

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes

DRUG: Fludarabine Phosphate

PROCEDURE: Leukapheresis

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being do...

RADIATION: Adaptive Bridging Radiation Therapy (ABRT)

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (rel...

BIOLOGICAL: Axicabtagene Ciloleucel

DRUG: Cyclophosphamide

DRUG: Fludarabine

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venet...

DRUG: Venetoclax

DRUG: Tazemetostat

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

BIOLOGICAL: SynKIR-310

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs f...

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the k...

DRUG: CAR.k.28

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Bendamustine

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R...

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will as...

DRUG: Epcoritamab

DRUG: Rituximab

DRUG: Lenalidomide

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feas...

BIOLOGICAL: 8/12-Day Production of Car-T Cells

BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells

BIOLOGICAL: 12-Day Production of Car-T Cells

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

BIOLOGICAL: P-CD19CD20-ALLO1

DRUG: Rimiducid

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relap...

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as deter...

DRUG: Zanubrutinib

DRUG: Rituximab

DRUG: Lenalidomide

DRUG: Obinutuzumab

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follic...

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may inter...

DRUG: Ibrutinib

BIOLOGICAL: Obinutuzumab

DRUG: Venetoclax

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Sign Up for Exclusive Diffuse Large B Cell Lymphoma Updates & Resources.

Thanks to our HealthTree Community for Diffuse Large B Cell Lymphoma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info